According to the Food and Drug Administration, a manufacturing plant owned by Ranbaxy Laboratories Ltd. falsified data and test results in approved and pending drug applications. The Wall Street Journal reported that the agency halted the review of drug applications made at Ranbaxy’s Paonta Sahib plant in India. Last September, the FDA banned Ranbaxy from importing more than 30 generic drugs into the country because of “manufacturing violations” it found at two company plants in India, including Paonta Sahib. Hopefully, this means most products made at that plant are no longer on shelves in this country. Such drugs include generic versions of the cholesterol-lowering drug Zocor and the heartburn treatment Zantac.
Source: Wall Street Journal
Contact us today for a free legal consultation with an experienced attorney.
Fields marked *may be required for submission.
If you would like to subscribe to the Jere Beasley Report digital edition, simply visit our Subscriptions page and provide the necessary information or call us at 800-898-2034.
Attorney Advertising - Prior results do not guarantee a similar outcome.